We haven’t seen a sector watch list as hot as cannabis since the technology industry took off. As fast moving as technology proved to be, it is projected to pale in comparison to the cannabis industry. While no one can predict the state-mandated legalization of medical and recreational cannabis use, one thing is for sure – mainstream Fortune 500 companies are in the game and that speaks volumes!
There are many marijuana stocks to keep an eye on, but the least risk will be felt with developed companies already in some type of parallel market. For those with a higher degree of risk acceptance, there are a few “new” companies focused only on the cannabis industry that have already shown impressive growth curves.
While B Green Consultants are not investment portfolio advisors and will bear no responsibility for future financial losses from anyone that acts based on this information, here are the top 3 cannabis stocks poised for growth, as we see it.
1 – The Scotts Miracle-Gro Company (NYSE: SMG)
Best known for the manufacturing, marketing and selling of a consumer line of lawn and garden products, Scott’s Miracle-Gro has thrown their proverbial hat into the ring. CEO Jim Hagedorn is betting on hydroponics. While ramping up ancillary products for the cannabis growth industry, in 2013 Hagedorn began the biggest acquisition in Miracle-Gro history since the 1990s. Scott’s Miracle-Gro paid Dutch grow lighting company Gavita $136 million, while it’s subsidiary, Hawthorne, just signed a deal to purchase Arizona-based Botanicare. General Hydroponics, also located in California, was purchased by Scott’s Miracle-Gro company for $130 million last year. Scott’s Miracle-Gro is a well established company who is believed to be setting themselves up for high volume hydroponic growth and product support.
2 – Toro Company (NYSE: TTC)
Another well established Fortune 500 company, Toro, is looking to market their line of residential and commercial landscaping products to the commercial growers market. It’s estimated that Toro could triple its share price if the legalization of marijuana was to pass on a large scale. Toro is, however, hedging their bets. Toro isn’t technically investing in new marijuana growth and harvesting equipment yet, such as is seen with Scotts. This makes Toro a safer bet.
3 – AbbVie Inc. (NYSE: ABBV)
AbbVie Inc., is best known for their Marinol drug – an FDA approved treatment for nausea in patients undergoing chemotherapy and being treated for loss of appetite while carrying an AIDS diagnosis. Marinol is a synthetic form of THC and is delivered by capsule. Although marijuana is considered a Schedule 1 drug by the DEA, Marinol is listed as a Schedule 3 drug. What this means is that the FDA believes the clinical benefits of Marinol outweigh the abuse potential. AbbVie Inc. also manufactures Humira, a biologics therapy used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. Though there are other pharmaceuticals in the AbbVie Inc. arsenal that include treatment for hormonal fluctuations, hypothyroidism, endometriosis, Parkinson’s disease, Parathyroidism and Cholesterol issues, The Street believes that the synthetic form of THC which they are currently producing as a Schedule 3 drug will receive the majority of their marketing dollars in the future. AbbVie Inc. is a riskier bet because the company is dependent not only on the continued legalization of marijuana, but it also risks the FDA coming in with drug schedule changes that would stop them from producing THC as a Schedule 3 drug. Bigger risk means potentially bigger rewards. Are you a cannabis entrepreneur who is looking to dig deep into the largest financial boom since Technology – and generate wealth in the process? Then register for your 7 day Free trial membership at B Green Consultants today!